Suvorexant
Treatment for Insomnia
Typical Dosage: 10-20 mg at bedtime
Effectiveness
62%
Safety Score
55%
Clinical Trials
39
Participants
9K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
10-20 mg at bedtime
Time to Effect
immediate
Treatment Duration
long-term
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
28(Treat 28 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$150
Side Effect Mgmt:$50
Total Annual:$2,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$4,400
Cost per Remission
$27,500
Suvorexant Outcomes
for Insomnia
Efficacy Outcomes
Overall Effectiveness
+62%
Response Rate
+50%
Remission Rate
+8%
Common Side Effects
Somnolence
+10%
Headache
+7%
Dizziness
+4%
Sources:
Active Clinical Trials
4 active trials recruiting for Suvorexant in Insomnia
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
NCT06655883RECRUITINGPHASE3
300 participants
INTERVENTIONAL
Baltimore, United States +2 more
Started: Oct 9, 2025
Efficacy of Suvorexant on Post-operative Sleep Disturbance
NCT05823844RECRUITINGPHASE4
92 participants
INTERVENTIONAL
New York, United States
Started: May 1, 2023
The Effects of Orexin Antagonism on Fear Extinction in PTSD
NCT06788522NOT YET RECRUITINGPHASE4
40.1K participants
INTERVENTIONAL
San Francisco, United States +1 more
Started: Jan 1, 2026
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
NCT05593653RECRUITINGPHASE4
61 participants
INTERVENTIONAL
Boston, United States
Started: Jan 6, 2023
Completed Clinical Trials
13 completed trials for Suvorexant in Insomnia
Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
NCT01059851COMPLETEDPHASE1
16 participants
INTERVENTIONAL
Started: May 24, 2010
Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia
NCT03034018COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Boston, United States
Started: May 25, 2017
A Pilot Study of Suvorexant for Insomnia in Parkinson Disease
NCT02729714COMPLETEDPHASE4
21 participants
INTERVENTIONAL
Kirkland, United States
Started: Apr 1, 2016
A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)
NCT01311882COMPLETEDPHASE1
28 participants
INTERVENTIONAL
Haarlem, Netherlands
Started: Apr 1, 2011
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
NCT01293006COMPLETEDPHASE1
25 participants
INTERVENTIONAL
Started: Mar 25, 2011
A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
NCT03158025COMPLETEDPHASE1
39 participants
INTERVENTIONAL
Toronto, Canada
Started: Apr 19, 2017
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
NCT01021813COMPLETEDPHASE3
781 participants
INTERVENTIONAL
Started: Dec 10, 2009
Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs
NCT03312517COMPLETEDPHASE4
12 participants
INTERVENTIONAL
Novi, United States
Started: Apr 15, 2018
Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)
NCT01043926COMPLETEDPHASE1
16 participants
INTERVENTIONAL
Started: Feb 22, 2010
To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia
NCT02849184COMPLETEDPHASE4
82 participants
INTERVENTIONAL
Fukuoka, Japan +2 more
Started: Jan 17, 2017
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
NCT00792298COMPLETEDPHASE2
254 participants
INTERVENTIONAL
Started: Nov 5, 2008
A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
NCT03110315COMPLETEDPHASE4
36 participants
INTERVENTIONAL
Kirkland, United States
Started: Mar 28, 2017
Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder
NCT02527564COMPLETEDPHASE4
61 participants
INTERVENTIONAL
Stanford, United States
Started: Sep 1, 2015
Showing 20 of 39 total trials